COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Immune Status in Solid Organ Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01070901
Recruitment Status : Completed
First Posted : February 18, 2010
Last Update Posted : February 5, 2013
Astellas Pharma Inc
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center

Brief Summary:
Immunosuppressive therapy protocols in solid organ transplantation are rudimentary, differ by transplant center and no practical strategies are available to guide an individuals' response to immune suppression. In this study we will conduct research to assess immunologic status in solid organ transplant recipients, predicting immune reconstitution and outcomes after transplant to better guide the use of immunosuppressive medications.

Condition or disease
Organ Transplants

Layout table for study information
Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Predictors of Immune Status in Solid Organ Transplantation
Study Start Date : May 2010
Actual Primary Completion Date : March 2012
Actual Study Completion Date : March 2012

Organ transplant recipients

Primary Outcome Measures :
  1. Immune Markers [ Time Frame: 0, 3, 6, 9, 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Tranplant clinic population

Inclusion Criteria:

  • Impending kidney transplant
  • Age >18
  • Able to provide informed consent and comply with the study procedures

Exclusion Criteria:

  • Age<18
  • Concomitant illness, which by decision of investigator, may compromise the ability to perform this trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01070901

Layout table for location information
United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Astellas Pharma Inc
Layout table for additonal information
Responsible Party: Dartmouth-Hitchcock Medical Center Identifier: NCT01070901    
Other Study ID Numbers: PROG-9F09
First Posted: February 18, 2010    Key Record Dates
Last Update Posted: February 5, 2013
Last Verified: February 2013